Precigen (NASDAQ:PGEN) Releases Earnings Results, Beats Estimates By $0.06 EPS

Precigen (NASDAQ:PGEN) issued its earnings results on Tuesday. The biotechnology company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.06, FiscalAI reports. Precigen had a positive return on equity of 484.64% and a negative net margin of 183.98%.The firm had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. The firm’s revenue for the quarter was up 6322.7% on a year-over-year basis.

Here are the key takeaways from Precigen’s conference call:

• PAPZIMEOS revenue surged to $53.1 million in Q2 from $21.6 million in Q1, a more than 145% sequential increase that drove Precigen to quarterly net income of $20.1 million, or $0.05 per diluted share.
• Commercial adoption continued to broaden, with more than 500 patients registered through PAPZIMEOS SUPPORT, approximately 315 million covered U.S. lives, and increasing use across major medical centers and community practices. Management said the permanent J-code effective April 1 has helped institutions establish routine reimbursement and treatment workflows.
• Management highlighted a broad FDA label, favorable safety profile, and durability data showing 83% of patients remained in complete response beyond three years as of the April 30 cutoff, with some patients exceeding four years without additional RRP treatment. PAPZIMEOS also received seven-year U.S. market exclusivity through August 2032.
• Precigen expects PAPZIMEOS gross margins to stabilize in the high-80% to low-90% range after remaining pre-launch inventory is sold, while R&D spending is expected to rise as pipeline programs advance. The company said cash, investments, and collection of receivables should fund operations through cash-flow breakeven by the end of 2026.
• The company remains on track to begin a pediatric PAPZIMEOS trial this year, while its EMA marketing application is under review. PRGN-2009 continues in Phase 2 trials with pembrolizumab in HPV-related head and neck and cervical cancers, with updated head-and-neck data expected later in 2026.

Precigen Trading Up 0.4%

PGEN stock traded up $0.03 during trading on Thursday, hitting $6.92. The company had a trading volume of 4,913,641 shares, compared to its average volume of 4,587,332. The firm has a 50-day moving average price of $5.12 and a 200-day moving average price of $4.46. Precigen has a 12 month low of $1.70 and a 12 month high of $7.23. The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of -6.63 and a beta of 1.02.

Insider Transactions at Precigen

In other news, CFO Harry Jr. Thomasian sold 171,429 shares of Precigen stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $5.53, for a total value of $948,002.37. Following the completion of the sale, the chief financial officer directly owned 354,535 shares of the company’s stock, valued at approximately $1,960,578.55. This trade represents a 32.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Rutul R. Shah sold 42,924 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $5.85, for a total value of $251,105.40. Following the sale, the chief operating officer owned 497,751 shares of the company’s stock, valued at approximately $2,911,843.35. The trade was a 7.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 956,500 shares of company stock valued at $5,248,371 over the last 90 days. 41.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Xponance LLC grew its stake in Precigen by 21.3% in the fourth quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,496 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Precigen by 6.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 2,993 shares in the last quarter. Intech Investment Management LLC grew its position in shares of Precigen by 5.2% in the 4th quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock valued at $263,000 after purchasing an additional 3,137 shares during the period. HighTower Advisors LLC grew its position in shares of Precigen by 4.2% in the 4th quarter. HighTower Advisors LLC now owns 104,560 shares of the biotechnology company’s stock valued at $437,000 after purchasing an additional 4,249 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Precigen by 10.3% during the 4th quarter. The Manufacturers Life Insurance Company now owns 56,006 shares of the biotechnology company’s stock worth $234,000 after buying an additional 5,222 shares during the period. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. Wall Street Zen downgraded shares of Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Citizens Jmp upped their target price on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, May 14th. HC Wainwright increased their target price on shares of Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Citigroup reissued an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $14.50.

Key Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Q2 results significantly exceeded expectations. Precigen reported adjusted earnings of $0.05 per share versus the consensus estimate of a $0.01 loss, while revenue reached $54.98 million—nearly double analyst expectations and up sharply year over year. Precigen Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: PAPZIMEOS® is driving commercial momentum. Product revenue totaled $53.1 million in Q2, more than doubling from the prior quarter. Precigen said patient-hub enrollment exceeded 500 and expects product revenue, combined with available cash and investments of $38.7 million, to support cash-flow break-even by year-end. The FDA also granted the product seven years of market exclusivity. Precigen Reports Second Quarter 2026 Financial Results
• Positive Sentiment: HC Wainwright raised its earnings outlook and maintained a Buy rating. The firm increased its FY2027 EPS forecast to $0.44 from $0.34, lifted estimates for Q4 2026 through Q4 2027, and raised its FY2030 forecast to $1.49 from $1.44. Its $18 price target implies substantial upside from recent trading levels. HC Wainwright Reiterates Buy Rating for Precigen
• Neutral Sentiment: Options activity was unusually high, indicating increased speculative interest, but the available report does not establish whether traders were predominantly bullish or bearish. Precigen Target of Unusually Large Options Trading
• Negative Sentiment: Insider selling remains a risk. Reported open-market transactions over the past six months show company insiders selling shares without reported purchases, including substantial sales by executives and director Randal Kirk. Separately, Precigen continues to use cash in operations, making the planned path to cash-flow break-even important for valuation.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.